Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q3 2015 · 10-Q
Revenue$180.00M$180.00M−1.6% vs Q3 2014 Net Income$21.40M$21.40M−41.8% vs Q3 2014 EPS Diluted$0.29$0.29−39.6% vs Q3 2014 Operating Income$35,700,000−35.4% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$25,500,000+163.0% Margins · derivedOperating margin19.8%−10.4 pt vs Q3 2014
Net margin11.9%−8.2 pt vs Q3 2014
ended Mar 31, 2015 · filed May 6, 2015 · 36 d after period end